Catalog No.
Product Name
Application
Product Information
Citations
-
DDP-4 inhibitor
Sitagliptin phosphate is an anti-diabetic (antihyperglycemic) drug of the dipeptidyl peptidase-4 (DPP-4) class. Inhibition of the enzyme DPP-4 is thought to increase Glucagon-like peptide-1 (GLP-1) which inhibits glucagon release , stimulates the insulin release and lowers blood glucose. -
DPP-4 Inhibitor
Linagliptin is a DPP-4 inhibitor, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).- Fen Zhuge, .et al. , Exp Neurol, 2024, Mar:373:114689 PMID: 38199510
-
GLP-1 receptor agonist
ixisenatide inhibit glucagon release, markedly reduce postprandial glucago. have a promoting effct in diabetes mellitus (T2DM). -
GLP-1 receptor agonist
Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist. -
GLP-1 agonist
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).- Tito Borner, .et al. , Cell Rep, 2020, Jun 16;31(11):107768 PMID: 32553160
-
GLP-1 receptor agonist
Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.- Liuqing Xi, .et al. , Peptides, 2025, Mar:185:171366 PMID: 39954860
-
GLP-1 receptor agonist
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes. -
GLP-1R agonist
GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist. -
GLP-1 receptor agonist
GLP-1 receptor agonist 1 is a glucagon-like peptide-1 (GLP-1) receptor agonist extracted from patent WO2018056453A1, Compound 67. -
glucagon-like peptide 1 receptor antagonist
GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM. -
DPP4 inhibitor
Vildagliptin (LAF237 dihydrate;NVP-LAF 237 dihydrate) is a dipeptidyl peptidase 4 (DPP4) inhibitor that delays the degradation of glucagon-like peptide-1 (GLP-1). -
GLP-1R agonist
PF-06882961 is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor agonist (GLP-1R) - Tirzepatide (LY3298176, GIP/GLP-1 RA, TZP) is a dual GIP/GLP-1 receptor agonist. Tirzepatide differentially induces internalization of the GIP and GLP-1 receptors with EC50 values of 18.2 nM and 18.1 nM, respectively.
-
GLP-1 antagonist
Avexitide (Exendin (9-39)) is a specific and competitive GLP-1 receptor antagonist. -
Glucagon receptor agonist
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity. - GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
- GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
- GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
-
GLP-1 receptor agonist
Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist. -
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7-36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).
-
GLP-1 agonist
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM). - HAEGT is the first N-terminal 1-5 residues of glucagon like peptide-1 (GLP-1) peptide, and the sequence is His-Ala-Glu-Gly-Thr. HAEGT acts as a competitive substrate for probing prime substrate binding sites of human dipeptidyl peptidase-IV (DPP-IV) 1, in which the N-terminal His-Ala is catalyzed cleavage by DPP-IV. HAEGT can be used in the research of diabetes, obesity.
- Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion.
-
GLP-1R Agonist
Pegloxenatide is a long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist. It exhibits various biological activities, including the reduction of blood glucose and lipids, weight management, anti-inflammatory effects, and promotion of wound healing, as well as providing protective effects on liver and heart tissues. Pegloxenatide is primarily utilized in research focused on type 2 diabetes and its associated complications. -
Artificial Insulin
Insulin Detemir is an artificial insulin that regulates blood glucose levels by mimicking the effects of natural insulin. It activates the secretion of GLP-1 through enhanced expression of Gcg, utilizing signaling pathways involving Akt and extracellular signal-regulated kinase (ERK) alongside CREB. This reagent is primarily used in research related to type 2 diabetes, facilitating studies on glucose metabolism and insulin sensitivity. -
IBAT Inhibitor
(S)-Elobixibat is a selective inhibitor of the intestinal bile acid transporter (IBAT). It effectively lowers LDL cholesterol levels, enhances serum levels of GLP-1, and promotes colonic motility, making it a valuable tool in metabolic syndrome research. This compound is utilized in studies related to constipation, dyslipidemia, non-alcoholic fatty liver disease, and liver tumors. -
GLP-1R Agonist/GIPR Antagonist
Maridebart cafraglutide is a novel peptide-antibody conjugate that serves as a GLP-1 receptor agonist and GIP receptor antagonist. This compound exhibits potent agonistic activity against GLP-1 receptors across species, with EC50 values of 24.4 pM for human, 5.7 pM for cynomolgus monkey, 2.4 pM for rat, and 123 pM for mouse. Additionally, it shows antagonistic effects on GIP receptors with IC50 values of 46.4 nM in human, 26.5 nM in cynomolgus monkey, and 822.3 nM in rat models. Maridebart cafraglutide is primarily used for investigating mechanisms of obesity and type 2 diabetes. -
GIP/GLP-1 Agonist
Ribupatide is a dual agonist targeting both gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptors. It exhibits significant antidiabetic activity, making it a valuable compound for research applications focused on metabolic disorders and diabetes management. Its dual mechanism may provide insights into the intricate regulation of glucose metabolism. -
GIP/GLP-1 Agnonist
Relsipatide is a dual agonist of the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This compound demonstrates significant potential in enhancing insulin secretion and reducing glucagon levels, making it a valuable tool in antidiabetic research. Its unique mechanism of action may contribute to improved glycemic control and metabolic regulation in diabetes studies. -
PEGylated Exenatide
Visepegenatide is a PEGylated form of Exenatide, primarily targeting GLP-1 receptors to enhance insulin secretion and improve beta-cell function. This compound demonstrates significant activity in reducing hyperglycemia and managing insulin resistance. Visepegenatide is a valuable tool for research focused on type 2 diabetes and related metabolic disorders. -
GIP/GLP Agonist
Enicepatide is a dual agonist for the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This compound is primarily investigated for its antidiabetic properties, contributing to glucose metabolism regulation and insulin secretion enhancement. Research applications include exploring its potential role in treating metabolic disorders and obesity-related conditions. -
GIP/GLP-1 Agonist
Astepatide is a dual agonist of the gastric inhibitory peptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor, which primarily influences glucose metabolism and insulin secretion. This compound demonstrates significant anti-diabetic activity, making it a valuable tool for research related to diabetes and metabolic disorders. Astepatide can aid in exploring mechanisms of action and therapeutic potential for obesity and type 2 diabetes. -
Anti-diabete Agent
Glyceollin III is a soybean-derived glyceollin that functions as an anti-diabetic agent. It enhances insulin-stimulated glucose uptake and promotes the secretion of glucagon-like peptide-1 (GLP-1). This compound is valuable for research focused on type 2 diabetes and its metabolic effects. -
DPP4 Inhibitor
Sitagliptin hydrochloride is a selective DPP4 inhibitor, demonstrating an IC50 of 19 nM. By inhibiting DPP4, this compound prevents the breakdown of incretin hormones, such as GLP-1 and GIP, ultimately increasing their active levels. Additionally, sitagliptin can stimulate GLP-1 secretion from intestinal L cells via the cAMP/PKA and ERK1/2 pathways, independent of DPP-4 inhibition. This reagent is applicable in research involving type 1 and type 2 diabetes, and it also exhibits protective effects on pancreatic islet grafts in type 1 diabetes models. -
Stable Isotope
Sitagliptin-d6 is a deuterium-labeled derivative of Sitagliptin, a selective DPP-4 inhibitor that demonstrates an IC50 of 19 nM. By inhibiting the degradation of incretins such as GLP-1 and GIP, Sitagliptin-d6 promotes increased levels of active glucagon-like peptides, thereby enhancing insulin secretion in a glucose-dependent manner. Additionally, it can stimulate GLP-1 secretion from intestinal L cells independently of DPP-4 inhibition, engaging the cAMP/PKA and ERK1/2 signaling pathways. This reagent is valuable for research on type 1 and type 2 diabetes, as well as the protective effects on pancreatic islet grafts. -
GPR119 Agonist
2-Oleoylglycerol is a GPR119 agonist that activates hGPR119 in transiently transfected COS-7 cells with an EC50 value of 2.5 μM. This lipid enhances the inflammatory response in macrophages and promotes fibrosis through the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. Additionally, 2-Oleoylglycerol stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. Its effects make it a valuable tool for research into non-alcoholic steatohepatitis (NASH) and related metabolic disorders. -
Stable Isotope
2-Oleoylglycerol-d5 is a deuterium-labeled derivative of 2-Oleoylglycerol, a known agonist of GPR119. It exhibits significant biological activity by activating human GPR119 with an EC50 of 2.5 μM in COS-7 cells, enhancing macrophage inflammatory responses and promoting fibrosis through the GPR119/TAK1/NF-κB/TGF-β1 signaling cascade. Additionally, this compound stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol-d5 is particularly useful for studying mechanisms underlying non-alcoholic steatohepatitis (NASH). -
PDD4 Inhibitor
Sitagliptin phosphate is a selective DPP4 inhibitor with a powerful mechanism of action, featuring an IC50 value of 19 nM. By inhibiting DPP4, this compound prevents the degradation of incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), resulting in enhanced active incretin levels. Additionally, it can directly stimulate GLP-1 secretion from intestinal L cells via the cAMP/PKA and ERK1/2 pathways, which operates independently of DPP-4. Sitagliptin phosphate is valuable for researching both type 1 and type 2 diabetes and demonstrates protective effects on pancreatic islet grafts in type 1 diabetes models. -
Stable Isotope
Sitagliptin-d4 phosphate is a deuterium-labeled derivative of Sitagliptin phosphate, a selective inhibitor of dipeptidyl peptidase-4 (DPP4) with an IC50 value of 19 nM. This compound increases the levels of active incretins by inhibiting the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Additionally, Sitagliptin-d4 phosphate can stimulate GLP-1 secretion from intestinal L cells through the activation of the cAMP/PKA and ERK1/2 pathways, independent of DPP-4. This reagent is valuable for research into type 1 and type 2 diabetes and can contribute to studies exploring pancreatic islet function. -
GLP-1R Agonist
Naperiglipron is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R) with an EC50 of 1.14 nM for human GLP-1R. This compound has demonstrated significant efficacy in reducing blood glucose levels in GLP-1R knock-in mouse models, indicating its potential for managing type II diabetes mellitus (T2DM) and obesity. Additionally, Naperiglipron inhibits phosphodiesterase 10A1 activity with an IC50 of 7.43 μM and exhibits weak hERG inhibitory activity, making it relevant for various metabolic research applications. -
DPP-IV Inhibitor
AGFAGDDAPR is a competitive and orally active inhibitor of dipeptidyl peptidase-IV (DPP-IV). By inhibiting DPP-IV, AGFAGDDAPR increases levels of glucagon-like peptide-1 (GLP-1), which stimulates insulin secretion, enhances β-cell function, and suppresses excessive α-cell proliferation, resulting in beneficial anti-diabetic effects. This peptide is suitable for investigating mechanisms and therapeutic approaches related to type 2 diabetes.
